Search Results for: stem cell biotech

Biotech California Cultured aims to sell lab-grown chocolate

California Cultured lab-grown chocolate. Pic by Paul Knoepfler.

I’m fascinated by the idea of making food from cells grown in a lab and especially the newest idea of lab-grown chocolate. While lab-grown meat has gotten the most attention, (see my recent post on test-tube meat: Not Old MacDonald’s Farm: is the future lab-grown meat?) I’d say that the coolest application of making food from

Biotech California Cultured aims to sell lab-grown chocolate Read More »

All about Altos Labs and $3B cellular rejuvenation push

Altos Labs PIs

I wrote briefly a few months ago about Altos Labs. It’s a new kind of biotech institute that is focused on cellular reprogramming. Now we know much more and it’s clear this is a huge deal. What’s in this article What is Altos Labs? | Cellular rejuvenation | Reprogramming oldness | Challenges | Altos Strategies | Analysis of

All about Altos Labs and $3B cellular rejuvenation push Read More »

16 predictions for stem cells & regenerative medicine in 2022

regenerative medicine, stem cells 2021

The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder.  Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021

16 predictions for stem cells & regenerative medicine in 2022 Read More »

Grading my 21 stem cell & regenerative medicine predictions for 2021

stem-cell-crystal-ball-300x3001

The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current

Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best

Mesoblast stock

A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »

Weekly reads: PRC2, 2 weird bits of news, pubs, COVID stem cell hype

PRC2 lineage commitment

I’d say the paper of the week is on how PRC2 mediated H3K27me3 can in some sense replace elements of DNA methylation to repress. Very cool. Here it is: Sex-specific chromatin remodelling safeguards transcription in germ cells, Nature. Weird stuff In a merger of opposites, City of Hope to buy Cancer Treatment Centers of America

Weekly reads: PRC2, 2 weird bits of news, pubs, COVID stem cell hype Read More »

Therapeutic misconception & the planned Duke Cryo-Cell cord clinic

Duke Cryo-Cell therapeutic misconception

One of the core problems in the world of unproven stem cell clinics is something called therapeutic misconception. I’ll talk more about that in a minute, but first, let me tell you what brought this to mind now. Surprisingly, the story starts at Duke University. A Duke cell therapy team and the biotech Cryo-Cell have big

Therapeutic misconception & the planned Duke Cryo-Cell cord clinic Read More »

Clade Therapeutics pursues universal cells for cancer therapy

Chad-Cowan CRISPR Therapeutics

Clade  Therapeutics has been pursuing the idea of using gene-editing to make universally compatible cells. The potential here is big. What if you could make cloaked stem cells that could be used to produce cellular therapies that could be given to most patients without fear of immune rejection? Clade Therapeutics Boston Business Journal covers the

Clade Therapeutics pursues universal cells for cancer therapy Read More »